Prepare to roll up your sleeves, because the battle for the ESI patient has only just begun. While Wall Street is busy calculating the earnings-per-share impact this will have on all relevant parties (at press time, Walgreens’ shares had consistently hovered around the $35 range, up almost $4 in the week following the announcement), the business of pharmacy retailing will return to block and tackle mode.
The Kessler Foundation and the Heldrich Center for Workforce Development last week released a research brief on disability employment titled “Strategies to Support Employer-Driven Initiatives to Recruit and Retain Employees with Disabilities” that explores the growing trend among employers in accommodating workers with disabilities.
In 2006, Time magazine added a twist to its annual “Person of the Year” cover story, replacing the usual picture of some prominent individual with a picture of a glossy computer screen to show that social networking had made “you” the person of the year. Now, the idea that it’s all about “you” has percolated into retail.
A number of smaller manufacturers of male contraceptives are launching into the market to challenge the big three: Church & Dwight (72.8% dollar share in the category), Ansell Healthcare (11.6% dollar share) and Reckitt Benckiser (11.5% dollar share).
MinuteClinic, the walk-in medical clinics inside CVS/pharmacy stores in 25 states and the District of Columbia, is gearing up for the back-to-school season by reminding parents that it is a one-stop location where students can get their required vaccinations and sports and college physicals as four states issue new immunization mandates.
So Walgreens and Express Scripts have buried the hatchet. The question is, can the nation’s top pharmacy retailer regain the billions of dollars in contracted prescription revenues it ceded to its competitors after the two sides severed relations in January? And, given the way Walgreens has adjusted and reset its growth strategy since then, does it matter that much?
In light of Thursday’s news that Walgreens will re-enter Express Scripts' broadest network on Sept. 15, CVS Caremark stated that it now is better able to clarify what it believes will be the overall estimate of the impact from the impasse for the remainder of 2012.
Employees with such chronic diseases as asthma, diabetes and high blood pressure spend fewer days out of the office when they are adherent to their medications, according to new research conducted by CVS Caremark and Truven Health Analytics (previously the healthcare business of Thomson Reuters).
Leveraging the deep understanding of its customer base via insights gained through its ExtraCare loyalty program, CVS/pharmacy officially unveiled on Thursday a new personalized digital experience on CVS.com, which features extensive health information and resources in addition to customized deals and savings information.
As much as CVS created a category of one for itself with its vertically integrated retail pharmacy-pharmacy benefit manager-clinic model, Walgreens has cast itself in a category of its own: A pharmacy-driven, global health-and-wellness company with the purchasing strength of more than 11,000 stores.
It’s been cited as one of the biggest health crises facing the United States and, if solved, the equivalent dollar value of a blockbuster drug. According to the latest statistics from pharmacy benefit manager Express Scripts, poor medication adherence costs the country $317 billion per year, an upgrade from the $290 billion calculated in a study released in 2009 by the New England Healthcare Institute.